David A. Siegel Imv Inc. Transaction History

Two Sigma Advisers, LP

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2021 Nov 15, 2021	SELL	$1.35 - $2.16 $30,510 - $48,816	-22,600 Closed	0 $0
Q2 2021 Aug 16, 2021	SELL	$2.12 - $3.24 $102,396 - $156,492	-48,300 Reduced 68.12%	22,600 $49,000
Q1 2021 May 17, 2021	SELL	$2.92 - $4.41 $87,600 - $132,300	-30,000 Reduced 29.73%	70,900 $235,000
Q4 2020 Feb 16, 2021	SELL	$2.9 - $4.4 $94,540 - $143,440	-32,600 Reduced 24.42%	100,900 $311,000
Q3 2020 Nov 16, 2020	BUY	$2.87 - $5.95 $383,145 - $794,325	133,500 New	133,500 $593,000

Ticker IMV
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 82,452,200
Description
IMV Inc. operates as a clinical-stage immuno-oncology company. The company develops a portfolio of therapies based on DPX its immune-educating technology platform for treatment of solid and hematological cancers. The company's lead drug candidate includes maveropepimut-S, a DPX-based immunotherapy that targets survivin-expressing cells that is P...

Get notified when there are updates to the investment portfolio of Two Sigma Advisers, LP, based on Form 13F filings with the SEC.

Stay updated on Two Sigma Advisers, LP and David A. Siegel with notifications on news.